Generics Bulletin is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hikma Is Halted By US Everolimus Method-Of-Use Patent

Executive Summary

While a Delaware district court incorrectly held Hikma’s West-Ward to a heightened standard on motivation to combine prior art, that error did not prove fatal to its decision to uphold the validity of a US patent protecting Novartis’s Afinitor everolimus treatment for RCC until May 2026.

 


Advertisement

Topics

Related Companies

What to read next

Advertisement
UsernamePublicRestriction

Register

GB140325

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel